Saudi, UK Regulators Sign Pact on Biotech Oversight
The Saudi Food and Drug Authority and Britain's MHRA agreed to cooperate on evaluating rare disease treatments, advanced therapies and biotechnology products.
Updated on Nov. 17, 2026 in Biotech

The Saudi Food and Drug Authority signed a memorandum of understanding with the UK's Medicines and Healthcare products Regulatory Agency in London. The agreement was signed by SFDA Chief Executive Officer Dr. Hisham bin Saad Al-Jadhey and MHRA Chief Executive Lawrence Tallon.
Why it matters
The memorandum builds on existing cooperation and a shared commitment to accelerating access to innovative treatments while maintaining safety, quality and efficacy standards. It is expected to help clarify regulatory requirements for developers at an early stage.
The memorandum covers exchanging expertise on artificial intelligence, computer modeling and simulation in clinical studies and trials, plus good manufacturing practices, quality systems, product testing and supply chain monitoring. The source does not state any measurable performance targets or timelines for these exchanges.
The players
Saudi Food and Drug Authority (SFDA)
The SFDA is Saudi Arabia's national regulator responsible for oversight of medicines, medical devices and food products.
Medicines and Healthcare products Regulatory Agency (MHRA)
The MHRA is the United Kingdom's regulator for medicines, medical devices and blood components, responsible for ensuring their safety and effectiveness.
The details
The agreement was signed on the sidelines of the Drug Information Association and MHRA Global Summit in London. The two sides also held discussions on cooperation priorities in light of recent scientific and regulatory developments, with efforts aimed at strengthening medical product safety and monitoring associated risks in both markets.
Timeline
November 16-17: Drug Information Association and MHRA Global Summit held in London.
November 17: SFDA and MHRA sign the memorandum of understanding.
The Tech Race
The memorandum extends the MHRA's regulatory framework for advanced therapies into a bilateral arrangement with Saudi Arabia's SFDA. It positions both regulators to evaluate biotechnology products and AI-assisted clinical trial methods in parallel.
Developers of rare disease treatments and advanced therapies may face clearer early-stage regulatory requirements across Saudi Arabia and the UK. Patients may see new treatments reach these markets sooner if the cooperation speeds evaluations while keeping safety standards intact.
The takeaway
Regulatory cooperation between national agencies can clarify requirements for biotech developers working across borders. Watch for follow-up announcements on joint evaluations as the memorandum is implemented.
Further reading
For broader context on drug approvals and regulatory policy, explore our Biotech coverage.



